SCHEMBL24460481

SCHEMBL24460481

COC(=O)c1cc2ncc(C)n2cc1Br

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.39
LMNA P02545 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
GAA P10253 5/20 0.38
KDM4E B2RXH2 4/20 0.38
ALDH1A1 P00352 4/20 0.38
GLA P06280 3/20 0.38
HPGD P15428 2/20 0.38
CYP1A2 P05177 4/20 0.38
CYP2C19 P33261 3/20 0.38
NPC1 O15118 1/20 0.38
TP53 P04637 1/20 0.38
RAB9A P51151 1/20 0.38
HSD17B10 Q99714 1/20 0.38
KMT2A Q03164 5/20 0.36
PKM P14618 2/20 0.36
TSHR P16473 2/20 0.36
HTT P42858 1/20 0.36
OPRK1 P41145 1/20 0.36
KDR P35968 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24460384 0.84 POLB (0.41) POLBLMNATDP1GAAKDM4E
SCHEMBL25148947 0.80 POLB (0.40) POLBGAAKDM4EKMT2ATSHR
SCHEMBL25149132 0.80 NR4A2 (0.38) POLBLMNATDP1GAAKDM4E
SCHEMBL24460390 0.78 GABRA1 (0.44) LMNATDP1GAAKDM4EALDH1A1
SCHEMBL24770222 0.76 LMNA (0.32) POLBLMNATDP1
SCHEMBL30521172 0.74 OPRK1 (0.41) POLBLMNATDP1HSD17B10OPRK1
SCHEMBL24460464 0.74 PIK3CA (0.39) KDM4EALDH1A1HPGDNPC1RAB9A
SCHEMBL19781784 0.73 TRPA1 (0.34) LMNAKDM4EALDH1A1NPC1RAB9A
SCHEMBL22717585 0.72 KDR (0.46) POLBLMNATDP1CYP1A2CYP2C19
SCHEMBL339175 0.72 POLB (0.38) POLBLMNATDP1GAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303569-A1 HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS ARISAN THERAPEUTICS INC. (US) 2023-09-28 US disclosed
WO-2022108849-A1 HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS ARISAN THERAPEUTICS INC. (US) 2022-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303569-A1 HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS C3AR1, C9, C1R POLB 4458/4885LMNA 680/4885TDP1 3576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.